Trial Profile

Multicenter, randomized, placebo controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate the efficacy and safety of BAY 2433334 in patients following an acute myocardial infarction

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Asundexian (Primary)
Indications Cardiovascular disorders; Myocardial infarction; Stroke; Thromboembolism; Thrombosis
Focus Adverse reactions; Therapeutic Use
Acronyms PACIFIC-AMI
Sponsors Bayer

27 Aug 2022 Results published in the Circulation
22 Aug 2022 According to Bayer media release, data from this trial will be presented at the European Society of Cardiology's 70th Annual Scientific Session (ESC.22).
04 Mar 2022 This trial has been completed in Czech Republic (End Date: 17 Feb 2022), according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com